EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Benevolent AI's enterprise value is €28.47 Mil.
Benevolent AI's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-80.80 Mil. Therefore, Benevolent AI's EV-to-EBITDA for today is -0.35.
The historical rank and industry rank for Benevolent AI's EV-to-EBITDA or its related term are showing as below:
XAMS:BAI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.15 Med: -0.7 Max: 0.19
Current: -0.35
During the past 6 years, the highest EV-to-EBITDA of Benevolent AI was 0.19. The lowest was -10.15. And the median was -0.70.
XAMS:BAI's EV-to-EBITDA is ranked worse than 100% of 449
companies
in the Biotechnology industry
Industry Median: 9.2
vs XAMS:BAI: -0.35
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Benevolent AI EV-to-EBITDA Historical Data
The historical data trend for Benevolent AI's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Benevolent AI's EV-to-EBITDA
For the Biotechnology subindustry, Benevolent AI's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Benevolent AI's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Benevolent AI's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Benevolent AI's EV-to-EBITDA falls into.
Benevolent AI EV-to-EBITDA Calculation
Benevolent AI's EV-to-EBITDA for today is calculated as:
Benevolent AI's current Enterprise Value is €28.47 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Benevolent AI's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-80.80 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Benevolent AI (XAMS:BAI) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Benevolent AI's PE Ratio for today is calculated as:
Benevolent AI's share price for today is €0.528.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Benevolent AI's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.623.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Benevolent AI's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XAMS:BAI has been successfully added to your 